Ionis Pharmaceuticals, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Ionis Pharmaceuticals is a biotechnology company focused on RNA-targeted therapeutics. The filing covers the three months ended March 31, 2023, with comparative results for the three months ended March 31, 2022. The company operates as one reportable segment and consolidates Akcea Therapeutics.
Ionis had four marketed medicines: QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA. Subsequent to quarter-end, the FDA granted accelerated approval for QALSODY on April 25, 2023, and accepted the eplontersen NDA with a December 22, 2023 PDUFA date.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $130.5 million | $141.9 million | Down 8.0% |
| Commercial revenue | $67.8 million | $72.3 million | Down 6.2% |
| R&D revenue | $62.8 million | $69.6 million | Down 9.9% |
| Operating expenses | $244.7 million | $199.4 million | Up 22.7% |
| Loss from operations | $(114.1) million | $(57.5) million | Loss increased |
| Net loss | $(124.3) million | $(65.2) million | Loss increased |
| Basic and diluted loss per share | $(0.87) | $(0.46) | Loss increased |
| Net cash used in operating activities | $(134.0) million | $(31.7) million | Use increased |
Approximate operating margin was negative 87.5% in Q1 2023 versus negative 40.5% in Q1 2022. Approximate net margin was negative 95.3% versus negative 45.9%.
- SPINRAZA royalties were $50.2 million, compared with $53.8 million. Global SPINRAZA sales declined 6% year over year to $443 million, primarily due to foreign exchange, fewer U.S. new-patient starts and channel dynamics.
- TEGSEDI and WAYLIVRA revenue increased to $6.5 million from $6.2 million. Licensing and other royalty revenue declined to $11.0 million from $12.3 million.
- R&D revenue included $24.4 million of eplontersen joint-development revenue, $20.3 million from Biogen-related activities and a $15.0 million GSK milestone for advancing bepirovirsen into Phase 3.
- Research, development and patent expense increased to $197.8 million from $161.1 million, while SG&A increased to $45.5 million from $34.1 million. Management attributed the increases to advancing the late-stage pipeline and pre-commercialization activities.
- Investment income rose to $18.6 million from $2.0 million, primarily due to higher interest rates and increased invested cash.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $309.0 million at March 31, 2023, compared with $276.5 million at December 31, 2022.
- Short-term investments were $2.038 billion, producing cash, cash equivalents and short-term investments of approximately $2.347 billion.
- Total assets were $2.885 billion and stockholders’ equity was $486.6 million. Accumulated deficit was $1.554 billion.
- Outstanding convertible notes consisted of $632.5 million of 0% notes due April 2026 and $548.8 million of 0.125% notes due December 2024, before unamortized issuance costs.
- Total contractual obligations disclosed, excluding the royalty-sale liability, were $1.489 billion, including $1.183 billion of convertible-note principal and interest obligations.
- The company reported no off-balance-sheet arrangements and stated that its disclosure controls were effective as of March 31, 2023.
Material changes versus the prior comparable period
- Revenue decreased $11.4 million, while operating expenses increased $45.3 million, resulting in a $56.6 million deterioration in operating loss.
- Net loss increased $59.2 million, primarily reflecting higher pipeline development and commercial-readiness spending, along with $15.5 million of interest expense related to the royalty transaction.
- Operating cash use increased by $102.3 million. Investing cash use increased to $325.6 million, principally because of purchases of short-term investments.
- In January 2023, Ionis received $500.0 million from Royalty Pharma for rights to a portion of future SPINRAZA and pelacarsen royalties. Ionis recorded a net liability of $505.1 million at quarter-end after transaction costs and accrued interest.
- Stock-based compensation increased modestly to $26.9 million from $26.2 million.
- Comprehensive loss improved to $115.8 million from $81.1 million loss only because of favorable unrealized debt-security gains; reported net loss materially worsened.
Guidance, outlook, commentary and risks
- Management expects operating expenses, excluding non-cash equity compensation, to continue increasing during the remainder of 2023 as late-stage medicines advance and commercialization preparations continue.
- The company had seven medicines in Phase 3 studies across nine indications, including eplontersen, olezarsen, donidalorsen, ION363, QALSODY, pelacarsen and bepirovirsen.
- Management expected data from the olezarsen Phase 3 BALANCE study in the second half of 2023 and anticipated completing enrollment in the donidalorsen Phase 3 OASIS-HAE study in mid-2023, with data expected in the first half of 2024.
- Royalty Pharma may provide up to $625 million of additional milestone payments, but those amounts depend on specified regulatory and commercial milestones, particularly for pelacarsen, and are not assured.
- The royalty-sale liability uses an estimated effective interest rate of 13.5%. Changes in SPINRAZA sales, pelacarsen approval or sales, competition and other factors could materially change future royalty payments and related accounting estimates.
- Key risks include clinical-trial failure or delay, regulatory and post-approval requirements, reimbursement and pricing pressure, competition, reliance on Biogen, AstraZeneca, GSK and Novartis, manufacturing and supply-chain constraints, intellectual-property disputes, product liability, cybersecurity, geopolitical disruption and the company’s history of operating losses.
- SPINRAZA revenue remains exposed to competition from gene therapy and oral therapies. TEGSEDI and WAYLIVRA face commercial limitations related to monitoring requirements, labeling restrictions and reliance on third-party distributors.
- A stockholder derivative litigation settlement concerning director compensation was approved on April 24, 2023 and did not materially affect the financial statements.
Most important facts for investors to verify
- Whether QALSODY approval and the eplontersen regulatory timeline translate into meaningful commercial revenue and milestone payments.
- SPINRAZA sales trends, royalty receipts and the effect of the Royalty Pharma arrangement on future cash flows.
- The pace and cost of Phase 3 programs and commercialization preparations, particularly for eplontersen, olezarsen and donidalorsen.
- Cash burn relative to approximately $2.35 billion of cash, cash equivalents and short-term investments, including the timing of expected operating losses.
- Repayment, conversion or refinancing requirements for the $548.8 million notes due in December 2024 and the $632.5 million notes due in April 2026.
- Conditions attached to the potential $625 million of additional Royalty Pharma payments and the sensitivity of the royalty liability to product performance.
- Clinical, regulatory, reimbursement, competitive and manufacturing developments that could reduce the value of the pipeline or marketed products.